Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases

J M Blazeby (Corresponding Author), P Fayers, T Conroy, O Sezer, J Ramage, M Rees, European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

BACKGROUND: There is a lack of valid patient-reported outcome (PRO) measures for hepatectomy or palliative treatment of colorectal hepatic metastases. This study examined the validity and reliability of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire liver module (QLQ-LMC21) in patients with liver metastases from colorectal cancer.

METHODS: Some 356 patients completed the core questionnaire (QLQ-C30), QLQ-LMC21 and a debriefing questionnaire before and 3 months after hepatectomy or palliative treatment. Construct, criterion and clinical validity were evaluated before and after treatment.

RESULTS: Questionnaire compliance was high; less than 1 per cent of data were missing from individual items. Modifications to the hypothesized scale structure produced four scales and nine single items with good reliability, clinical, criterion and construct validity. The QLQ-LMC21 distinguished between patients selected for surgery or palliative treatment in nine of these 13. Significant changes in PROs were observed before and after treatment. The new module discriminated between clinically distinct groups of patients and measured aspects of quality of life not covered in the core questionnaire.

CONCLUSION: The EORTC QLQ-LMC21 is a valid and reliable questionnaire module to use with the QLQ-C30 in assessing PROs in hepatectomy or palliative treatment for colorectal liver metastases.
Original languageEnglish
Pages (from-to)291-298
Number of pages8
JournalBritish Journal of Surgery
Volume96
Issue number3
Early online date17 Feb 2009
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Organizations
Neoplasm Metastasis
Palliative Care
Liver
Hepatectomy
Research
Neoplasms
Therapeutics
Quality of Life
Reproducibility of Results
Compliance
Surveys and Questionnaires
Patient Reported Outcome Measures
Colorectal Neoplasms

Keywords

  • colorectal neoplasms
  • female
  • hepatectomy
  • humans
  • liver neoplasms
  • male
  • middle aged
  • palliative care
  • patient compliance
  • quality of life
  • questionnaires
  • reproducibility of results
  • treatment outcome

Cite this

Blazeby, J. M., Fayers, P., Conroy, T., Sezer, O., Ramage, J., Rees, M., & European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group (2009). Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. British Journal of Surgery, 96(3), 291-298. https://doi.org/10.1002/bjs.6471

Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. / Blazeby, J M (Corresponding Author); Fayers, P; Conroy, T; Sezer, O; Ramage, J; Rees, M; European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group.

In: British Journal of Surgery, Vol. 96, No. 3, 03.2009, p. 291-298.

Research output: Contribution to journalArticle

Blazeby, JM, Fayers, P, Conroy, T, Sezer, O, Ramage, J, Rees, M & European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group 2009, 'Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases', British Journal of Surgery, vol. 96, no. 3, pp. 291-298. https://doi.org/10.1002/bjs.6471
Blazeby, J M ; Fayers, P ; Conroy, T ; Sezer, O ; Ramage, J ; Rees, M ; European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group. / Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. In: British Journal of Surgery. 2009 ; Vol. 96, No. 3. pp. 291-298.
@article{0e59d8ec64ac45cf85d0cc07b1ee01c3,
title = "Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases",
abstract = "BACKGROUND: There is a lack of valid patient-reported outcome (PRO) measures for hepatectomy or palliative treatment of colorectal hepatic metastases. This study examined the validity and reliability of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire liver module (QLQ-LMC21) in patients with liver metastases from colorectal cancer. METHODS: Some 356 patients completed the core questionnaire (QLQ-C30), QLQ-LMC21 and a debriefing questionnaire before and 3 months after hepatectomy or palliative treatment. Construct, criterion and clinical validity were evaluated before and after treatment. RESULTS: Questionnaire compliance was high; less than 1 per cent of data were missing from individual items. Modifications to the hypothesized scale structure produced four scales and nine single items with good reliability, clinical, criterion and construct validity. The QLQ-LMC21 distinguished between patients selected for surgery or palliative treatment in nine of these 13. Significant changes in PROs were observed before and after treatment. The new module discriminated between clinically distinct groups of patients and measured aspects of quality of life not covered in the core questionnaire. CONCLUSION: The EORTC QLQ-LMC21 is a valid and reliable questionnaire module to use with the QLQ-C30 in assessing PROs in hepatectomy or palliative treatment for colorectal liver metastases.",
keywords = "colorectal neoplasms, female, hepatectomy, humans, liver neoplasms, male, middle aged, palliative care, patient compliance, quality of life, questionnaires, reproducibility of results, treatment outcome",
author = "Blazeby, {J M} and P Fayers and T Conroy and O Sezer and J Ramage and M Rees and {European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group}",
note = "Acknowledgements This study was supported by a grant from the Pelican Cancer Foundation, a Medical Research Council Clinician Scientist Award to J.M.B. and, in Berlin, by a research grant from Deutsche Krebshilfe (Bonn, Germany). The authors thank Mrs J. Nicklin, Mrs B. King and Mrs I. Leonard for collecting the quality of life data in Bristol, Basingstoke and Nancy respectively. They also thank G. Velikova and C. Johnson for comments on the manuscript. The authors declare no conflict of interest.",
year = "2009",
month = "3",
doi = "10.1002/bjs.6471",
language = "English",
volume = "96",
pages = "291--298",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "British Journal of Surgery",
number = "3",

}

TY - JOUR

T1 - Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases

AU - Blazeby, J M

AU - Fayers, P

AU - Conroy, T

AU - Sezer, O

AU - Ramage, J

AU - Rees, M

AU - European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group

N1 - Acknowledgements This study was supported by a grant from the Pelican Cancer Foundation, a Medical Research Council Clinician Scientist Award to J.M.B. and, in Berlin, by a research grant from Deutsche Krebshilfe (Bonn, Germany). The authors thank Mrs J. Nicklin, Mrs B. King and Mrs I. Leonard for collecting the quality of life data in Bristol, Basingstoke and Nancy respectively. They also thank G. Velikova and C. Johnson for comments on the manuscript. The authors declare no conflict of interest.

PY - 2009/3

Y1 - 2009/3

N2 - BACKGROUND: There is a lack of valid patient-reported outcome (PRO) measures for hepatectomy or palliative treatment of colorectal hepatic metastases. This study examined the validity and reliability of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire liver module (QLQ-LMC21) in patients with liver metastases from colorectal cancer. METHODS: Some 356 patients completed the core questionnaire (QLQ-C30), QLQ-LMC21 and a debriefing questionnaire before and 3 months after hepatectomy or palliative treatment. Construct, criterion and clinical validity were evaluated before and after treatment. RESULTS: Questionnaire compliance was high; less than 1 per cent of data were missing from individual items. Modifications to the hypothesized scale structure produced four scales and nine single items with good reliability, clinical, criterion and construct validity. The QLQ-LMC21 distinguished between patients selected for surgery or palliative treatment in nine of these 13. Significant changes in PROs were observed before and after treatment. The new module discriminated between clinically distinct groups of patients and measured aspects of quality of life not covered in the core questionnaire. CONCLUSION: The EORTC QLQ-LMC21 is a valid and reliable questionnaire module to use with the QLQ-C30 in assessing PROs in hepatectomy or palliative treatment for colorectal liver metastases.

AB - BACKGROUND: There is a lack of valid patient-reported outcome (PRO) measures for hepatectomy or palliative treatment of colorectal hepatic metastases. This study examined the validity and reliability of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire liver module (QLQ-LMC21) in patients with liver metastases from colorectal cancer. METHODS: Some 356 patients completed the core questionnaire (QLQ-C30), QLQ-LMC21 and a debriefing questionnaire before and 3 months after hepatectomy or palliative treatment. Construct, criterion and clinical validity were evaluated before and after treatment. RESULTS: Questionnaire compliance was high; less than 1 per cent of data were missing from individual items. Modifications to the hypothesized scale structure produced four scales and nine single items with good reliability, clinical, criterion and construct validity. The QLQ-LMC21 distinguished between patients selected for surgery or palliative treatment in nine of these 13. Significant changes in PROs were observed before and after treatment. The new module discriminated between clinically distinct groups of patients and measured aspects of quality of life not covered in the core questionnaire. CONCLUSION: The EORTC QLQ-LMC21 is a valid and reliable questionnaire module to use with the QLQ-C30 in assessing PROs in hepatectomy or palliative treatment for colorectal liver metastases.

KW - colorectal neoplasms

KW - female

KW - hepatectomy

KW - humans

KW - liver neoplasms

KW - male

KW - middle aged

KW - palliative care

KW - patient compliance

KW - quality of life

KW - questionnaires

KW - reproducibility of results

KW - treatment outcome

U2 - 10.1002/bjs.6471

DO - 10.1002/bjs.6471

M3 - Article

C2 - 19224519

VL - 96

SP - 291

EP - 298

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 3

ER -